RA CAPITAL MANAGEMENT, L.P. Q3 2018 Filing
Filed November 14, 2018
Portfolio Value
$1.9T
Holdings
26
Report Date
Q3 2018
Filing Type
13F-HR
All Holdings (26 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | WVEWAVE LIFE SCIENCES LTD | 7,512,049 | $375.6B | 20.08% | |
| 2 | ASNDASCENDIS PHARMA A S | 4,240,536 | $300.5B | 16.06% | |
| 3 | SLDBSOLID BIOSCIENCES INC | 2,689,444 | $126.9B | 6.78% | |
| 4 | —ENDOCYTE INC | 6,196,143 | $110.0B | 5.88% | |
| 5 | —ZOGENIX INC | 1,878,768 | $93.2B | 4.98% | |
| 6 | —MYOVANT SCIENCES LTD | 3,451,859 | $91.6B | 4.90% | |
| 7 | BCRXBIOCRYST PHARMACEUTICALS | 9,234,692 | $70.5B | 3.77% | |
| 8 | —RA PHARMACEUTICALS INC | 3,851,808 | $69.7B | 3.73% | |
| 9 | IFRXINFLARX NV | 1,967,848 | $67.5B | 3.61% | |
| 10 | —IMMUNOMEDICS INC | 3,119,778 | $65.0B | 3.47% | |
| 11 | —DICERNA PHARMACEUTICALS INC | 3,933,489 | $60.0B | 3.21% | |
| 12 | RYTMRHYTHM PHARMACEUTICALS INC | 1,950,332 | $56.9B | 3.04% | |
| 13 | ARVNARVINAS INC | 3,138,412 | $52.9B | 2.83% | |
| 14 | SG7SAGE THERAPEUTICS INC | 350,933 | $49.6B | 2.65% | |
| 15 | CRNXCRINETICS PHARMACEUTICALS INC | 1,701,017 | $48.7B | 2.61% | |
| 16 | TGTXTG THERAPEUTICS INC | 8,198,337 | $45.9B | 2.45% | |
| 17 | —MOMENTA PHARMACEUTICALS INC | 1,558,357 | $41.0B | 2.19% | |
| 18 | KALVKALVISTA PHARMACEUTICALS INC | 1,441,070 | $31.9B | 1.70% | |
| 19 | —EIDOS THERAPEUTICS INC | 2,162,671 | $21.6B | 1.15% | |
| 20 | KALAKALA PHARMACEUTICALS INC | 2,113,236 | $20.9B | 1.12% | |
| 21 | —PROGENICS PHARMACEUTICALS INC | 3,030,303 | $19.0B | 1.02% | |
| 22 | SCPHSCPHARMACEUTICALS INC | 2,857,143 | $16.8B | 0.90% | |
| 23 | APLSAPELLIS PHARMACEUTICALS INC | 900,000 | $16.0B | 0.86% | |
| 24 | IOVAIOVANCE BIOTHERAPEUTICS INC | 1,121,153 | $12.6B | 0.67% | |
| 25 | GLYCEURGLYCOMIMETICS INC | 253,547 | $3.7B | 0.20% | |
| 26 | —PROTEON THERAPEUTICS INC | 1,337,462 | $2.6B | 0.14% |